Clinical Trial

A Study to Evaluate Solrikitug in Participants With COPD (ZION)

Study acronym: ZION
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).
Protocol Amendment History 4 changes
critical Enrollment closed, study ongoing 2026-08-12
notable Trial sites reduced: 118 -> 110 locations 2026-08-12
notable Primary completion pushed: 2026-06-30 -> 2026-09-30 2026-08-12
minor Completion pushed: 2026-10-31 -> 2027-02-01 2026-08-12
Trial Details
NCT Number NCT06496620
Lead Sponsor Uniquity One (UNI)
Collaborators: DevPro Biopharma
Conditions COPD
Enrollment 182 participants
Start Date 2024-08-14
Primary Completion 2026-09-30 (estimated)
Study Completion 2027-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-11